298 results
8-K
EX-99.1
TOVX
Theriva Biologics Inc
23 Apr 24
Regulation FD Disclosure
7:00am
results and benefits,; the ability to obtain regulatory approval for commercialization of product candidates or to comply with ongoing regulatory
8-K
EX-99.1
TOVX
Theriva Biologics Inc
22 Apr 24
Regulation FD Disclosure
4:36pm
and benefits; the ability to obtain regulatory approval for commercialization of product candidates or to comply with ongoing regulatory requirements
8-K
EX-99.1
TOVX
Theriva Biologics Inc
16 Apr 24
Regulation FD Disclosure
8:00am
, the ability to initiate and complete clinical trials on time and achieve the desired results and benefits, continuin g c linical trial enrollment
8-K
EX-99.1
qlpku 7cfi65guc
25 Mar 24
Theriva™ Biologics Reports Full-Year 2023 Operational Highlights and Financial Results
7:40am
8-K
EX-99.1
dbeaebzgb m0ez
7 Feb 24
Regulation FD Disclosure
8:10am
8-K
EX-99.1
c9fasol k2
8 Jan 24
Regulation FD Disclosure
8:10am
8-K
EX-99.1
c1cp4tb
13 Nov 23
Theriva™ Biologics Reports Third Quarter 2023 Operational Highlights and Financial Results
8:10am
8-K
EX-99.1
a7v21ah d3osgahrt
23 Oct 23
Regulation FD Disclosure
7:10am
8-K
EX-99.1
uk6vh5so1u
17 Oct 23
Regulation FD Disclosure
6:05am
DEFR14A
1qsdqi0hr2r wsawi
16 Aug 23
Revised proxy
5:24pm
8-K
EX-99.1
2hsenm xfq4a5sufxu
8 Aug 23
Theriva™ Biologics Reports Second Quarter 2023 Operational Highlights and Financial Results
8:10am
8-K
EX-99.1
7b90gbkg2bof6vsi
2 Aug 23
Regulation FD Disclosure
9:22am
8-K
EX-99.1
xpcuhf en73cm1n6
27 Jun 23
Theriva Biologics Announces Orphan Drug Designation Granted by the U.S. FDA for VCN-01 for the Treatment of Pancreatic Cancer
5:11pm